EFPIA On How EU Can Become A ‘World Leader’ In Life Sciences
Report Draws On 60 Case Studies Of Regulatory Hurdles
More agile regulatory processes, a much shorter period for the European Commission to make new drug approval decisions, and a firm legal basis for the European Medicines Agency in assessing combination products. These are among proposals put forward by Europe’s R&D-based pharmaceutical industry amid moves to revise the EU medicines legislation.
